Journal of Clinical Oncology 13(8): 2123-2139, 1995. is available online.
Journal of Clinical Oncology 13(8): 2123-2139, 1995. may be available online for subscribers.
Pappo AS, Shapiro DN, Crist WM, et al.
To review key developments in biology and therapy of rhabdomyosarcoma (RMS) since the early 1970s.
Patients and Methods:
The literature regarding biology, therapy, and late effects of therapy through March 1995 was reviewed.
The two major histiotypes, embryonal and alveolar, are characterized by specific genetic abnormalities that provide clues to mechanisms of tumor induction. Alveolar tumors, for example, often possess a chromosomal translocation [t(2;13)(q35;q14)] that fuses the PAX3 gene in band 2q35 with the FKHR gene in band 13q14, creating a novel chimeric protein that could inappropriately activate normal targets of the PAX3 gene product, thereby contributing to tumorigenesis. Recognition of prognostically important patient groups primarily identified by tumor extent, site, and histology, and development of effective risk-based multimodal therapy in randomized trials, have increased long-term survival in RMS from 25% in 1970 to more than 70% in current studies. The most significant recent gain in therapeutic results was realized in patients with gross residual tumor after biopsy.
Contemporary risk-based therapy cures more than two thirds of children with RMS while minimizing acute and late effects. Increased dose-intensity of known effective agents with hematopoietic growth factor support, new agents, and hyperfractionated irradiation are being evaluated in hopes of further improving therapy. Recent discovery of novel genetic features in this tumor should lead to better methods of diagnosis and risk assessment, and ultimately to identification of molecular targets for specific treatment. (133 Refs)
Rheinische Friedrich- Wilhelms- Universität Bonn